Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.

Haematologica - 1 Jul 2017

Deng Andrew L, Kim Yu Ri, Lichtenstein Emily A, O'Connor Owen A, Deng Changchun

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to CD79 Antigens
Share to Lymphoma, Large B-Cell, Diffuse
Share to Myeloid Differentiation Factor 88

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Piperidines

Share to Positron Emission Tomography Computed Tomography

Share to Pyrazoles

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 28341730
DOI: 10.3324/haematol.2016.161893
PMCID: PMC5566054

Genes

MYD88

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.PMID 28341730Read ↗

[Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].Semantic proximity Read ↗

An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.Semantic proximity Read ↗

Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.Semantic proximity Read ↗

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.Semantic proximity Read ↗

Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement.Semantic proximity Read ↗

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.Semantic proximity Read ↗

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.Semantic proximity Read ↗

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.Semantic proximity Read ↗

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.Semantic proximity Read ↗

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Semantic proximity Read ↗

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.